Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.71 |
| ▸ | RAB9A | P51151 | 6/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.71 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.71 |
| ▸ | ATM | Q13315 | 1/20 | 0.71 |
| ▸ | SCD | O00767 | 2/20 | 0.69 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 4/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.64 |
| ▸ | HPGD | P15428 | 3/20 | 0.61 |
| ▸ | KLK7 | P49862 | 1/20 | 0.61 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.58 |
| ▸ | GFER | P55789 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13329390 | 0.89 | MAP3K5 (0.83) | NPC1RAB9AKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL16562169 | 0.88 | NPC1 (0.73) | NPC1RAB9AKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL4912185 | 0.88 | SCD (0.73) | NPC1RAB9AKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL21568214 | 0.87 | NPC1 (0.71) | NPC1RAB9AKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL2190326 | 0.87 | LRRK2 (0.72) | NPC1RAB9AKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL22130146 | 0.86 | SCD (0.87) | NPC1RAB9AKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL31219331 | 0.86 | SCD (0.87) | NPC1RAB9AKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL14807662 | 0.86 | MAP3K5 (0.70) | NPC1RAB9AKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL13329360 | 0.86 | HSD17B1 (0.74) | NPC1RAB9AKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL2190685 | 0.86 | NPC1 (0.70) | NPC1RAB9AKDM4ESMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019217509-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | HB THERAPEUTICS INC. (US) | 2019-11-14 | — | — | WO | disclosed |
| CN-1440383-A | PPAR gamma modulators | SANKYO CO (JP) | 2003-09-03 | — | — | CN | disclosed |
| US-20030134859-A1 | PPAR-gamma modulator | SANKYO COMPANY, LIMITED (JP) | 2003-07-17 | — | — | US | disclosed |
| EP-1277729-A1 | PPAR (GAMMA) MODULATORS | Sankyo Company, Limited (JP) | 2003-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134859-A1 | PPAR-gamma modulator | PPARG, PPARA, PPARD | NPC1 1152/4885RAB9A 1179/4885KDM4E 2489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.